



www.bioinformation.net
Volume 21(9)



Research Article

Received September 1, 2025; Revised September 30, 2025; Accepted September 30, 2025, Published September 30, 2025

DOI: 10.6026/973206300213071

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by A Prashanth

E-mail: phyjunc@gmail.com

Citation: Vijakar *et al.* Bioinformation 21(9): 3071-3075 (2025)

Prospective study on smoking and postoperative complications in breast reconstruction surgery

Shreyanshi Satyambhai Vijakar¹, Vishal Mruthyunjaya Kalmani², Mansoor Thekkinithethil³, Loisen Nathan Daniel^{4,*} & Sailesh IS Kumar⁵

¹Department of Pathology, Narendra Modi medical college, Ahmedabad, Gujarat, India; ²Department of Emergency Medicine, Barking, Havering and Redbridge University Hospitals NHS Trust, Essex, United Kingdom; ³Department of Trauma and Orthopedics, Junior Clinical Fellow Trauma and Orthopaedics, Swansea Bay University Health Board JCF in T&O, United Kingdom; ⁴Department of Emergency Medicine/intensive care/general medicine, Best Hospital, Tamil Nadu, India; ⁵Department of Surgery, Madras Medical College, Tamil Nadu, India; *Corresponding author

Affiliation URL:

<https://www.amcmet.org/>

<https://www.bhrhospitals.nhs.uk/>

<https://sbuhbcareers.nhs.wales/>
<https://www.thebesthospital.in>
<https://www.tnmgrmu.ac.in/>

Authors contacts:

Shreyanshi Satyambhai Vijakar - E-mail: Shreyanshivijakar@gmail.com; Phone: +91 97262 00706
Vishal Mruthyunjaya Kalmani - E-mail: vishal.kalmani@nhs.net; Phone: +447405881521
Mansoor Thekkinithetil - E-mail: Mansoor00100@gmail.com; Phone: +918904638941
Loisen Nathan Daniel - E-mail: lsn.dnl@gmail.com; Phone: +91 86670 98606
Sailesh I S Kumar - E-mail: Sailesh.isk@gmail.com; Phone: +91 9486813072

Abstract:

The impact of smoking on postoperative complications in 125 women undergoing breast reconstruction surgery is of interest. Hence, patients were stratified into current smokers, former smokers and non-smokers and followed for 30 days postoperatively. Current smokers had significantly higher rates of wound dehiscence, infection and flap necrosis compared to non-smokers. Former smokers showed intermediate complication rates. Thus, we show the critical need for smoking cessation strategies prior to reconstructive breast surgery.

Keywords: Smoking, breast reconstruction, postoperative complications, wound healing, flap necrosis, prospective study

Background:

Smoking is a cause of many postoperative complications, including delayed wound healing, tissue necrosis and reconstructive flap loss. However, there is a paucity of evidence-based guidelines for smoking cessation in patients undergoing implant-based breast surgery [1]. Breast reconstruction following mastectomy is a critical component of comprehensive breast cancer care, offering physical restoration and psychological benefits [2]. However, the procedure is not without risk and postoperative complications can significantly impact aesthetic outcomes, patient satisfaction and long-term recovery [3]. Among the modifiable risk factors, cigarette smoking has consistently been associated with impaired wound healing, increased risk of infection and compromised flap viability in various surgical settings [4]. Nicotine and other tobacco-derived toxins contribute to vasoconstriction, impaired oxygen delivery, reduced collagen synthesis and increased oxidative stress all of which negatively affect tissue repair [5]. Despite these well-known physiological effects, many patients' undergoing breast reconstruction are not adequately counseled or supported in smoking cessation prior to surgery [6]. Moreover, few prospective studies have systematically evaluated the differential risks between current smokers, former smokers and non-smokers in this specific surgical population [7]. Therefore, it is of interest to investigate the relationship between smoking status and the incidence of postoperative complications in women undergoing breast reconstruction.

Materials and Methods:

This prospective observational study was conducted over a 12-month period in the Department of Plastic and Reconstructive Surgery at a tertiary care academic hospital. A total of 125 female patients undergoing breast reconstruction surgery following mastectomy for breast cancer were enrolled after obtaining informed consent. Both immediate and delayed reconstructions were included, encompassing autologous flap procedures (such

as DIEP and TRAM flaps) and implant-based reconstructions. Patients with severe systemic illness, prior radiotherapy to the chest wall, active infections, or poorly controlled diabetes were excluded to eliminate confounding influences on wound healing. Smoking history was obtained during preoperative evaluation and verified through patient interviews and medical records. Participants were categorized into three groups: current smokers (those actively smoking within 30 days of surgery), former smokers (abstinent for at least 30 days) and non-smokers (never smoked or smoked fewer than 100 cigarettes lifetime). Data collected included age, body mass index (BMI), comorbidities (hypertension, diabetes), alcohol use, type and timing of reconstruction, duration and intensity of smoking (pack-years) and medication history. All patients underwent standardized surgical techniques and perioperative care protocols. Postoperative follow-up was conducted for 30 days to document wound-related and systemic complications. Primary outcomes included surgical site infection, wound dehiscence, hematoma, seroma, flap necrosis, delayed wound healing and need for reoperation. Data analysis involved comparison of complication rates across the three smoking groups using chi-square tests for categorical variables and ANOVA for continuous variables. Logistic regression was used to assess the independent impact of smoking status on complications, controlling for age, BMI, comorbidities and type of reconstruction. A p-value <0.05 was considered statistically significant.

Results:

This prospective study demonstrated a clear association between smoking status and increased postoperative complications in breast reconstruction surgery. Current smokers had significantly higher rates of wound-related issues—including infection, dehiscence and flap necrosis—compared to non-smokers and former smokers. Former smokers showed intermediate complication rates, reinforcing the benefit of preoperative

cessation. **Table 1** shows the patient cohort was predominantly middle-aged, with a majority undergoing implant-based reconstruction. Current smokers had higher BMI and more comorbidity. **Table 2** shows current smokers experienced the highest complication rate overall, especially for infections and delayed healing. **Table 3** shows wound infection and delayed healing was significantly more frequent in autologous reconstructions among current smokers. **Table 4** shows pack-years correlated positively with complication rates among current and former smokers. **Table 5** shows Logistic regression showed smoking status as an independent predictor of

postoperative complications. **Table 6** shows most complications among smokers occurred within the first 10 days post-surgery. **Table 7** shows the reoperation rate was significantly higher among smokers, mainly for debridement and flap salvage. **Table 8** shows current smokers had significantly longer hospital stays compared to non-smokers, driven primarily by infection and wound-related delays. **Table 9** shows patients who developed complications reported significantly lower satisfaction scores postoperatively, particularly among smokers. **Table 10** shows a significant proportion of smoker’s required delayed initiation of adjuvant cancer therapy due to wound-related issues.

Table 1: Baseline demographic and clinical characteristics by smoking status

Variable	Current Smokers (n=38)	Former Smokers (n=27)	Non-Smokers (n=60)	p-value
Mean Age (years)	45.3 ± 7.2	47.8 ± 6.9	46.1 ± 6.4	0.31
BMI (kg/m²)	27.6 ± 3.1	26.2 ± 2.8	25.4 ± 2.7	0.02
Diabetes (%)	18.4	11.1	8.3	0.18
Hypertension (%)	21.0	14.8	10.0	0.22
Type of Reconstruction (%)				
- Implant-based	63.2	66.7	70.0	0.74
- Autologous flap	36.8	33.3	30.0	

Table 2: Postoperative complications within 30 days by smoking status

Complication	Current Smokers (%)	Former Smokers (%)	Non-Smokers (%)	p-value
Any Complication	60.5	37.0	16.7	<0.001
Surgical Site Infection	28.9	14.8	6.7	0.002
Wound Dehiscence	23.7	11.1	5.0	0.01
Flap Necrosis	18.4	7.4	1.7	0.003
Hematoma	10.5	7.4	3.3	0.21
Seroma	13.2	7.4	5.0	0.28
Delayed Healing	31.6	14.8	6.7	<0.001
Reoperation Required	21.1	7.4	1.7	0.001

Table 3: Complication rates by type of reconstruction and smoking status

Type of Surgery	Complication	Smokers (%)	Non-Smokers (%)	p-value
Implant-Based	SSI	23.1	6.0	0.01
	Delayed Healing	26.9	7.1	0.008
Autologous Flap	Flap Necrosis	35.7	3.7	<0.001
	Reoperation	28.6	3.7	<0.001

Table 4: Complication rate stratified by smoking exposure (pack-years)

Smoking Exposure (Pack-Years)	n	Any Complication (%)	p-value
<5	17	23.5	
5–10	22	40.9	
>10	26	61.5	<0.001

Table 5: Multivariable logistic regression: predictors of any postoperative complication

Variable	Adjusted OR	95% CI	p-value
Current Smoker	4.75	2.01–11.23	<0.001
Former Smoker	2.23	0.88–5.66	0.09
BMI > 27	1.94	0.92–4.12	0.08
Diabetes	2.56	0.94–6.94	0.06
Autologous Reconstruction	2.14	1.03–4.43	0.04

Table 6: Timing of complication onset by smoking status

Complication Onset (Days Post-op)	Current Smokers (%)	Former Smokers (%)	Non-Smokers (%)
0–3 Days	28.9	11.1	6.7
4–7 Days	23.7	11.1	5.0
8–14 Days	7.9	11.1	3.3
15–30 Days	0.0	3.7	1.7

Table 7: Reasons for reoperation by smoking status

Reason for Reoperation	Smokers (n=8)	Former Smokers (n=2)	Non-Smokers (n=1)
Flap Necrosis/Debridement	5	1	0
Hematoma Evacuation	2	1	1
Implant Exposure	1	0	0

Table 8: Length of postoperative hospital stay by smoking status

Smoking Status	Mean Length of Stay (Days) ± SD	p-value
Current Smokers	6.9 ± 2.4	<0.001
Former Smokers	5.1 ± 1.8	
Non-Smokers	3.8 ± 1.5	

Table 9: Patient-reported satisfaction scores (0-10 scale) at 1-month follow-up

Group	Mean Satisfaction Score ± SD	p-value
Smokers with Complications	5.2 ± 1.6	<0.001
Non-Smokers with Complications	6.8 ± 1.3	
Patients Without Complications	8.7 ± 0.9	

Table 10: Delay in initiation of adjuvant therapy (>6 weeks post-surgery)

Smoking Status	n (%) Experiencing Delay	p-value
Current Smokers	10 (26.3%)	<0.001
Former Smokers	3 (11.1%)	
Non-Smokers	2 (3.3%)	

Discussion:

This prospective study highlights the significant impact of smoking on postoperative outcomes in breast reconstruction surgery. Our findings clearly demonstrate that current smokers are at markedly increased risk for complications, including surgical site infection, delayed wound healing, flap necrosis and the need for reoperation [8]. Former smokers also experienced elevated complication rates, though substantially lower than current smokers, suggesting a partial but not complete reversal of smoking-related surgical risk with cessation [9]. Nicotine-induced vasoconstriction, carbon monoxide-mediated hypoxia and impaired fibroblast activity are well-established mechanisms by which smoking interferes with wound healing [10]. These pathophysiologic effects were evident in our cohort, particularly in autologous flap reconstructions, where perfusion and microvascular integrity are critical. Smokers undergoing flap-based procedures experienced high rates of necrosis and reoperation, reinforcing the importance of adequate perfusion in high-risk surgical environments. The correlation between pack-years and complication rates provides additional evidence for a dose-dependent effect of smoking on wound healing [11]. Patients with greater than 10 pack-years had the highest overall complication rates, suggesting that both current behavior and cumulative exposure are clinically relevant. This observation supports early and aggressive preoperative counseling, especially for long-term smokers. Interestingly, most complications in current smokers manifested within the first week postoperatively, indicating that acute surgical stress in a compromised vascular environment may precipitate early wound failure [12]. Reoperation was largely driven by flap necrosis and infection, which not only jeopardize aesthetic outcomes but also prolong hospitalization and increase healthcare costs. The logistic regression analysis confirmed smoking as an independent predictor of postoperative morbidity, even after adjusting for other confounding factors such as BMI, diabetes and reconstruction type [13]. This finding underscores the necessity of incorporating smoking status into preoperative risk stratification models and reinforces the role of multidisciplinary perioperative interventions [14]. Our study also highlights a window of opportunity in former smokers, who had notably fewer complications than active smokers. This

supports existing evidence that even short-term cessation before surgery (30 days or more) can lead to improved surgical outcomes. However, their intermediate complication rates also suggest that the physiological effects of long-term tobacco exposure are not fully reversible in the short term. In clinical practice, these results advocate for stronger preoperative protocols emphasizing smoking cessation, ideally initiated well in advance of planned breast reconstruction. Patients should be informed of the heightened risks associated with smoking and institutions should facilitate access to cessation resources as a routine part of surgical planning [15]. In summary, smoking is a potent, modifiable risk factor for adverse outcomes in breast reconstruction surgery. The data strongly support integrating tobacco cessation as a core element of preoperative care to enhance healing, reduce complications and improve reconstructive success.

Conclusion:

Smoking significantly increases the risk of postoperative complications in breast reconstruction, including infection, wound dehiscence and flap necrosis. Former smokers show reduced but still elevated risk compared to non-smokers. Preoperative smoking cessation is essential to improve surgical outcomes and recovery.

Acknowledgement:

We acknowledge that the first and second author contributed equally to this paper and hence they are considered as joint first author

References:

[1] Zucker I et al. *Cureus*. 2021 **13**:e18876. [PMID: 34804725]
[2] Elston JB et al. *Plast Surg Hand Surg*. 2017 **51**:131. [PMID: 28328633]
[3] Klasson S et al. *J Plast Surg Hand Surg*. 2016 **50**:167. [PMID: 27125256]
[4] Joy MT et al. *J Plast Reconstr Aesthet Surg*. 2018 **71**:1310. [PMID: 29781858]
[5] Laporta R et al. *J Reconstr Microsurg*. 2017 **33**:429. [PMID: 28061518]
[6] Liu AS et al. *Plast Reconstr Surg*. 2011 **127**:1790. [PMID: 21228744]

- [7] Gräsbeck HL *et al.* *BJS Open*. 2023 **7**:zrad016. [PMID: 37086402]
 - [8] Laporta R *et al.* *J Plast Surg Hand Surg*. 2017 **51**:94. [PMID: 28319433]
 - [9] Gfrerer L *et al.* *J Plast Reconstr Aesthet Surg*. 2015 **68**:172. [PMID: 25626807]
 - [10] Theocharidis V *et al.* *J Plast Reconstr Aesthet Surg*. 2018 **71**:249. [PMID: 29426809]
 - [11] Fischer JP *et al.* *J Plast Surg Hand Surg*. 2013 **47**:227. [PMID: 23865900]
 - [12] Nahabedian MY *et al.* *Plast Reconstr Surg*. 2012 **130**:1076. [PMID: 23096984]
 - [13] Sørensen LT *et al.* *Arch Surg*. 2012 **147**:373. [PMID: 22508785]
 - [14] Alsanad M *et al.* *Perioper Med (Lond)*. 2025 **14**:5. [PMID: 39794839]
 - [15] Theadom A *et al.* *Tob Control*. 2006 **15**:352. [PMID: 16998168]
-